[CAS NO. 2413192-92-2] HBV-IN-30
PRODUCTS SPECIFICATIONS [2413192-92-2]
DESCRIPTION [2413192-92-2]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 493.73 |
| Molecular Formula | C22H18BrClO6 |
| SMILES | ClC1=C2C(C(C=C(C3=CC(Br)=C(C=C3)OCCO[C@@H]4C[C@@H](C4)C(O)=O)O2)=O)=CC=C1 |
Summary
In Vitro
HBV-IN-30 (ex44; 24 h) inhibits HBeAg levels and cell viability with an IC
50
value of 0.57 μM in HepDES19 cells. HepDES19 is the cell line that produces cccDNA
[1]
.
HBV-IN-30 (5 days) decreases cccDNA levels in HepDES19 cells in a dose-dependent manner
[1]
.
HBV-IN-30 (9 days; primary human hepatocyte (PHH)) has anti-HBV effect and inhibits HBeAg with an IC
50
value of 0.04 μM
[1]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.